Literature DB >> 32307792

cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.

David N Louis1, Pieter Wesseling2,3, Kenneth Aldape4, Daniel J Brat5, David Capper6,7, Ian A Cree8, Charles Eberhart9, Dominique Figarella-Branger10, Maryam Fouladi11, Gregory N Fuller12, Caterina Giannini13,14, Christine Haberler15, Cynthia Hawkins16, Takashi Komori17, Johan M Kros18, H K Ng19, Brent A Orr20, Sung-Hye Park21, Werner Paulus22, Arie Perry23, Torsten Pietsch24, Guido Reifenberger25,26, Marc Rosenblum27, Brian Rous8,28, Felix Sahm29,30,31, Chitra Sarkar32, David A Solomon23, Uri Tabori33, Martin J van den Bent34, Andreas von Deimling29,30, Michael Weller35, Valerie A White8, David W Ellison8,20.   

Abstract

cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT-NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles-relating to classification categories, approaches to classification, nomenclature, and grading-that the group hopes will also inform the future classification of CNS neoplasms.
© 2020 International Society of Neuropathology.

Entities:  

Keywords:  brain tumors; central nervous system; classification; neoplasms

Year:  2020        PMID: 32307792     DOI: 10.1111/bpa.12832

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  122 in total

Review 1.  The cIMPACT-NOW updates and their significance to current neuro-oncology practice.

Authors:  L Nicolas Gonzalez Castro; Pieter Wesseling
Journal:  Neurooncol Pract       Date:  2020-08-29

2.  The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Chinmay Sharma; Muhammad Ibrahim; Abhishta Bhandari; Matthew Riggs; Rhondda Jones; Arian Lasocki
Journal:  Neuroradiology       Date:  2021-04-03       Impact factor: 2.804

Review 3.  Major Features of the 2021 WHO Classification of CNS Tumors.

Authors:  Heather L Smith; Nitin Wadhwani; Craig Horbinski
Journal:  Neurotherapeutics       Date:  2022-05-16       Impact factor: 7.620

4.  Clinical implications of molecular analysis in diffuse glioma stratification.

Authors:  Masahiro Mizoguchi; Nobuhiro Hata; Daisuke Kuga; Ryusuke Hatae; Yojiro Akagi; Yuhei Sangatsuda; Yutaka Fujioka; Kosuke Takigawa; Yusuke Funakoshi; Satoshi O Suzuki; Toru Iwaki
Journal:  Brain Tumor Pathol       Date:  2021-07-15       Impact factor: 3.298

Review 5.  A pediatric cerebral tumor with MN1 alteration and pathological features mimicking carcinoma metastasis: may the terminology "high grade neuroepithelial tumor with MN1 alteration" still be relevant?

Authors:  Ramazan Sari; Meric A Altinoz; Enis Ozyar; Ayca Ersen Danyeli; Ilhan Elmaci
Journal:  Childs Nerv Syst       Date:  2021-07-16       Impact factor: 1.475

6.  TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?

Authors:  Caterina Giannini; Felice Giangaspero
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

7.  Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.

Authors:  Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain
Journal:  J Neurooncol       Date:  2021-03-04       Impact factor: 4.130

Review 8.  The immune landscape of common CNS malignancies: implications for immunotherapy.

Authors:  Martina Ott; Robert M Prins; Amy B Heimberger
Journal:  Nat Rev Clin Oncol       Date:  2021-06-11       Impact factor: 66.675

9.  Polymorphous Low-Grade Neuroepithelial Tumor of the Young (PLNTY): Molecular Profiling Confirms Frequent MAPK Pathway Activation.

Authors:  Cristiane M Ida; Derek R Johnson; Asha A Nair; Jaime Davila; Thomas M Kollmeyer; Kay Minn; Numrah M Fadra; Jessica R Balcom; Kar-Ming A Fung; Dong Kun Kim; Timothy J Kaufmann; Benjamin R Kipp; Kevin C Halling; Robert B Jenkins; Caterina Giannini
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-27       Impact factor: 3.685

Review 10.  Imaging of the glioma microenvironment by TSPO PET.

Authors:  Bastian Zinnhardt; Federico Roncaroli; Claudia Foray; Erjon Agushi; Bahiya Osrah; Gaëlle Hugon; Andreas H Jacobs; Alexandra Winkeler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-03-15       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.